Illumina, Inc.
Illumina Reports Q2 2026 Financial Results and Updates Guidance
Summary
Illumina, Inc. reported financial results for the second quarter of fiscal year 2026, showing a 9.5% increase in revenue to $1.16 billion. The company reported GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5%. GAAP diluted EPS was $1.35, and non-GAAP diluted EPS was $1.31. Illumina updated its fiscal year 2026 guidance, expecting total revenue between $4.60-$4.64 billion, ROW organic revenue growth greater than 5%, non-GAAP operating margin of 23.4%-23.6%, and non-GAAP diluted EPS of $5.30-$5.40.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement